Generated: April 27, 2017
|Title:||Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic|
|Abstract:||The invention consists of a combination of a substance that increases the intragastric pH and an acid degradable antibacterial compound. By this combined product regimen it will be possible to obtain maximal local antibacterial effect of acid degradable antibiotics as well as enhanced bioavailability of the active antibiotic, thus resulting in higher amounts of the active compound in the gastric mucosa due to secretion of weak bases. Both pharmacological effects contribute to drastically increased antimicrobial capacity of acid degradable antibiotics to be used against local infections in the gastrointestinal tract causing gastritis and/or peptic ulcer. The invention also selects to the use of said combination and a process for the preparation thereof.|
|Inventor(s):||Eek; Arne T. (Trosa, SE), Sj ostrand; Sven Erik (S odert alje, SE)|
|Assignee:||Aktiebolaget Astra (Sodertalje, SE)|
1. A synergistic combination comprising from about 1-200 mg omeprazole or a pharmaceutically acceptable salt thereof and from about 250 mg to 10 mg clarithromycin for the treatment of
gastritis and peptic ulcer.
2. A method of orally administering an acid degradable antibiotic so as to increase its bioavailability comprising an effective amount of the synergistic combination of claim 1 to a human.